Table 1.

Response to JQ1 in various glioblastoma samples

IDIC50, nmol/LEmax, %Subtype (32)EGFR (38)p53 (38)Rb (35)PTEN (38)
GBM615090ClassicvIIIR273CGain
GBM840047ClassicHD
GBM1020025MesenchymalLoss
GBM1212095Classic5,3 Osplice
GBM1630029MesenchymalR273CLossHD
GBM2230044MesenchymalLoss
GBM3920052MesenchymalvIII
GBM43200086MesenchymalF270C
GBM4650040ProneuralvIIILoss
T410530083NDNDNDNDND
T430216085NDNDNDNDND
T45976088NDNDNDNDND
VU1036950059NDNDNDNDND
VU1082713065NDNDNDNDND
VU1101470060NDNDNDNDND

NOTE: Glioblastoma samples with a “GBM” prefix were short-term neurosphere cultures derived from primary glioblastoma xenograft lines serially passaged in mice. Samples with a “T” prefix were prospectively enriched CD133+ glioblastoma stem cells. Samples with a “VU” prefix were primary cultures directly isolated from patient surgical specimens (passage 3–7). IC50 values were determined after 5-day JQ1 treatment. The maximal effects (Emax) represented the inhibition rates of JQ1 at 5 μmol/L. Data represent the mean of 3 independent experiments.

Abbreviations: vIII, EGFR variant III; HD, homozygous deletion; ND, not determined.